A Review of New Findings in Adult T-cell Leukemia–Lymphoma: A Focus on Current and Emerging Treatment Strategies

Olivier Hermine, Juan Carlos Ramos, Kensei Tobinai

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Adult T-cell leukemia–lymphoma (ATL), a rare and aggressive T-cell malignancy caused by human T-cell lymphotropic virus type 1 (HTLV-1), is associated with a poor prognosis. Evidence-based standard treatment options are lacking and outcomes are generally unsatisfactory, particularly for patients with relapsed or refractory disease. Continued research is contributing to changing treatment landscape as a number of existing and investigational agents are evaluated. We describe the epidemiology of HTLV-1 and ATL, discuss the biology behind the disease, review current treatment practices and guidelines, and provide an overview of emerging therapies in ATL, with a focus on those for relapsed or refractory disease.

Original languageEnglish (US)
Pages (from-to)135-152
Number of pages18
JournalAdvances in Therapy
Volume35
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

T-Lymphocytes
Human T-lymphotropic virus 1
Therapeutics
Practice Guidelines
Epidemiology
Research
Neoplasms

Keywords

  • Adult T-cell leukemia–lymphoma
  • Chemotherapy
  • Human T-cell lymphotropic virus type 1
  • Oncology
  • Relapsed/refractory disease
  • Targeted agents

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

A Review of New Findings in Adult T-cell Leukemia–Lymphoma : A Focus on Current and Emerging Treatment Strategies. / Hermine, Olivier; Carlos Ramos, Juan; Tobinai, Kensei.

In: Advances in Therapy, Vol. 35, No. 2, 01.02.2018, p. 135-152.

Research output: Contribution to journalReview article

@article{83c1c3cb19fd4f188172f2ac72ef845e,
title = "A Review of New Findings in Adult T-cell Leukemia–Lymphoma: A Focus on Current and Emerging Treatment Strategies",
abstract = "Adult T-cell leukemia–lymphoma (ATL), a rare and aggressive T-cell malignancy caused by human T-cell lymphotropic virus type 1 (HTLV-1), is associated with a poor prognosis. Evidence-based standard treatment options are lacking and outcomes are generally unsatisfactory, particularly for patients with relapsed or refractory disease. Continued research is contributing to changing treatment landscape as a number of existing and investigational agents are evaluated. We describe the epidemiology of HTLV-1 and ATL, discuss the biology behind the disease, review current treatment practices and guidelines, and provide an overview of emerging therapies in ATL, with a focus on those for relapsed or refractory disease.",
keywords = "Adult T-cell leukemia–lymphoma, Chemotherapy, Human T-cell lymphotropic virus type 1, Oncology, Relapsed/refractory disease, Targeted agents",
author = "Olivier Hermine and {Carlos Ramos}, Juan and Kensei Tobinai",
year = "2018",
month = "2",
day = "1",
doi = "10.1007/s12325-018-0658-4",
language = "English (US)",
volume = "35",
pages = "135--152",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Health Communications Inc.",
number = "2",

}

TY - JOUR

T1 - A Review of New Findings in Adult T-cell Leukemia–Lymphoma

T2 - A Focus on Current and Emerging Treatment Strategies

AU - Hermine, Olivier

AU - Carlos Ramos, Juan

AU - Tobinai, Kensei

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Adult T-cell leukemia–lymphoma (ATL), a rare and aggressive T-cell malignancy caused by human T-cell lymphotropic virus type 1 (HTLV-1), is associated with a poor prognosis. Evidence-based standard treatment options are lacking and outcomes are generally unsatisfactory, particularly for patients with relapsed or refractory disease. Continued research is contributing to changing treatment landscape as a number of existing and investigational agents are evaluated. We describe the epidemiology of HTLV-1 and ATL, discuss the biology behind the disease, review current treatment practices and guidelines, and provide an overview of emerging therapies in ATL, with a focus on those for relapsed or refractory disease.

AB - Adult T-cell leukemia–lymphoma (ATL), a rare and aggressive T-cell malignancy caused by human T-cell lymphotropic virus type 1 (HTLV-1), is associated with a poor prognosis. Evidence-based standard treatment options are lacking and outcomes are generally unsatisfactory, particularly for patients with relapsed or refractory disease. Continued research is contributing to changing treatment landscape as a number of existing and investigational agents are evaluated. We describe the epidemiology of HTLV-1 and ATL, discuss the biology behind the disease, review current treatment practices and guidelines, and provide an overview of emerging therapies in ATL, with a focus on those for relapsed or refractory disease.

KW - Adult T-cell leukemia–lymphoma

KW - Chemotherapy

KW - Human T-cell lymphotropic virus type 1

KW - Oncology

KW - Relapsed/refractory disease

KW - Targeted agents

UR - http://www.scopus.com/inward/record.url?scp=85041556246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041556246&partnerID=8YFLogxK

U2 - 10.1007/s12325-018-0658-4

DO - 10.1007/s12325-018-0658-4

M3 - Review article

C2 - 29411267

AN - SCOPUS:85041556246

VL - 35

SP - 135

EP - 152

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

IS - 2

ER -